PRKAR2A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29637723	0.94	9/20
SCHEMBL24473663	0.52	8/20
SCHEMBL25758456	0.46	8/20
SCHEMBL24473534	0.46	8/20
SCHEMBL24473539	0.53	7/20
SCHEMBL24473602	0.52	7/20
SCHEMBL24473339	0.51	7/20
SCHEMBL24473505	0.51	7/20
SCHEMBL24473579	0.46	7/20
SCHEMBL24473637	0.46	7/20
SCHEMBL26181835	0.36	7/20
SCHEMBL17568826	0.52	6/20
SCHEMBL18053128	0.52	6/20
SCHEMBL24473416	0.46	5/20
SCHEMBL17880428	0.49	2/20
SCHEMBL18053760	0.48	2/20
SCHEMBL24473338	0.45	2/20
SCHEMBL18824835	0.30	2/20
SCHEMBL21218596	0.30	2/20
SCHEMBL21218597	0.30	2/20

Clinical trials — most relevant to PRKAR2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients	PHASE2	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Investigation of Asprosin a Novel Adipokine in Periodontitis	nan	COMPLETED
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Stress and Treatment Response in Puerto Rican Children With Asthma	nan	COMPLETED
Hypotaurine Supplementation Benefits in Cryopreservation	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PRKAR2A binder may also engage these)

Protein	Name	Similarity
P00515	—	0.998	P00515 →
P12368	—	0.997	P12368 →
P31322	—	0.997	P31322 →
P12369	—	0.993	P12369 →
P31324	—	0.988	P31324 →
P12367	—	0.985	P12367 →
PRKAR2B	cAMP-dependent protein kinase type II-beta regulatory subunit	0.985	landscape →
P16905	—	0.969	P16905 →
P31319	—	0.965	P31319 →
Q9C1C2	—	0.947	Q9C1C2 →
O14448	—	0.945	O14448 →
O88506	—	0.944	O88506 →
Q863I2	—	0.943	Q863I2 →
Q6P9R2	—	0.941	Q6P9R2 →
Q01386	—	0.941	Q01386 →
Q62696	—	0.940	Q62696 →
A0A8I5ZNK2	—	0.940	A0A8I5ZNK2 →
Q5PYH5	—	0.939	Q5PYH5 →
Q9Z1W9	—	0.939	Q9Z1W9 →
Q5R495	—	0.937	Q5R495 →
A0A8C0TYJ0	—	0.936	A0A8C0TYJ0 →
OXSR1	Serine/threonine-protein kinase OSR1	0.936	landscape →
STK39	STE20/SPS1-related proline-alanine-rich protein kinase	0.935	landscape →
Q12959	—	0.935	Q12959 →
Q811D0	—	0.934	Q811D0 →
Q68FK8	—	0.930	Q68FK8 →
Q28C55	—	0.929	Q28C55 →
P78352	—	0.929	P78352 →
MAPKAPK2	MAP kinase-activated protein kinase 2	0.929	landscape →
AKT1	RAC-alpha serine/threonine-protein kinase	0.928	landscape →